vs
BillionToOne, Inc.（BLLN）与EXACT SCIENCES CORP（EXAS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是BillionToOne, Inc.的10.5倍（$878.4M vs $83.5M）。BillionToOne, Inc.净利率更高（6.8% vs -9.8%，领先16.6%）。BillionToOne, Inc.同比增速更快（117.4% vs 23.1%）。EXACT SCIENCES CORP自由现金流更多（$120.4M vs $6.5M）
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
BLLN vs EXAS — 直观对比
营收规模更大
EXAS
是对方的10.5倍
$83.5M
营收增速更快
BLLN
高出94.3%
23.1%
净利率更高
BLLN
高出16.6%
-9.8%
自由现金流更多
EXAS
多$114.0M
$6.5M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $83.5M | $878.4M |
| 净利润 | $5.7M | $-86.0M |
| 毛利率 | 69.9% | 70.1% |
| 营业利润率 | 11.5% | -9.4% |
| 净利率 | 6.8% | -9.8% |
| 营收同比 | 117.4% | 23.1% |
| 净利润同比 | 138.3% | 90.1% |
| 每股收益（稀释后） | $0.10 | $-0.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLLNEXAS
| Q4 25 | — | $878.4M | ||
| Q3 25 | $83.5M | $850.7M | ||
| Q2 25 | — | $811.1M | ||
| Q1 25 | — | $706.8M | ||
| Q4 24 | — | $713.4M | ||
| Q3 24 | $38.4M | $708.7M | ||
| Q2 24 | — | $699.3M | ||
| Q1 24 | — | $637.5M |
净利润BLLNEXAS
| Q4 25 | — | $-86.0M | ||
| Q3 25 | $5.7M | $-19.6M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | — | $-101.2M | ||
| Q4 24 | — | $-864.6M | ||
| Q3 24 | $-14.9M | $-38.2M | ||
| Q2 24 | — | $-15.8M | ||
| Q1 24 | — | $-110.2M |
毛利率BLLNEXAS
| Q4 25 | — | 70.1% | ||
| Q3 25 | 69.9% | 68.6% | ||
| Q2 25 | — | 69.3% | ||
| Q1 25 | — | 70.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | 52.6% | 69.4% | ||
| Q2 24 | — | 69.8% | ||
| Q1 24 | — | 70.0% |
营业利润率BLLNEXAS
| Q4 25 | — | -9.4% | ||
| Q3 25 | 11.5% | -3.0% | ||
| Q2 25 | — | -0.3% | ||
| Q1 25 | — | -13.6% | ||
| Q4 24 | — | -122.8% | ||
| Q3 24 | -32.9% | -5.6% | ||
| Q2 24 | — | -3.8% | ||
| Q1 24 | — | -16.7% |
净利率BLLNEXAS
| Q4 25 | — | -9.8% | ||
| Q3 25 | 6.8% | -2.3% | ||
| Q2 25 | — | -0.1% | ||
| Q1 25 | — | -14.3% | ||
| Q4 24 | — | -121.2% | ||
| Q3 24 | -38.8% | -5.4% | ||
| Q2 24 | — | -2.3% | ||
| Q1 24 | — | -17.3% |
每股收益（稀释后）BLLNEXAS
| Q4 25 | — | $-0.45 | ||
| Q3 25 | $0.10 | $-0.10 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | — | $-0.54 | ||
| Q4 24 | — | $-4.69 | ||
| Q3 24 | $-1.47 | $-0.21 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | $-0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.2M | $964.7M |
| 总债务越低越好 | $55.0M | — |
| 股东权益账面价值 | $-239.5M | $2.4B |
| 总资产 | $327.5M | $5.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BLLNEXAS
| Q4 25 | — | $964.7M | ||
| Q3 25 | $195.2M | $1.0B | ||
| Q2 25 | — | $858.4M | ||
| Q1 25 | — | $786.2M | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $946.8M | ||
| Q1 24 | — | $652.1M |
总债务BLLNEXAS
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BLLNEXAS
| Q4 25 | — | $2.4B | ||
| Q3 25 | $-239.5M | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.4B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | $-242.9M | $3.2B | ||
| Q2 24 | — | $3.2B | ||
| Q1 24 | — | $3.1B |
总资产BLLNEXAS
| Q4 25 | — | $5.9B | ||
| Q3 25 | $327.5M | $5.9B | ||
| Q2 25 | — | $5.8B | ||
| Q1 25 | — | $5.7B | ||
| Q4 24 | — | $5.9B | ||
| Q3 24 | — | $6.7B | ||
| Q2 24 | — | $6.7B | ||
| Q1 24 | — | $6.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.8M | $151.7M |
| 自由现金流经营现金流 - 资本支出 | $6.5M | $120.4M |
| 自由现金流率自由现金流/营收 | 7.7% | 13.7% |
| 资本支出强度资本支出/营收 | 8.8% | 3.6% |
| 现金转化率经营现金流/净利润 | 2.42× | — |
| 过去12个月自由现金流最近4个季度 | — | $356.8M |
8季度趋势，按日历期对齐
经营现金流BLLNEXAS
| Q4 25 | — | $151.7M | ||
| Q3 25 | $13.8M | $219.9M | ||
| Q2 25 | — | $89.0M | ||
| Q1 25 | — | $30.8M | ||
| Q4 24 | — | $47.1M | ||
| Q3 24 | — | $138.7M | ||
| Q2 24 | — | $107.1M | ||
| Q1 24 | — | $-82.3M |
自由现金流BLLNEXAS
| Q4 25 | — | $120.4M | ||
| Q3 25 | $6.5M | $190.0M | ||
| Q2 25 | — | $46.7M | ||
| Q1 25 | — | $-365.0K | ||
| Q4 24 | — | $10.7M | ||
| Q3 24 | — | $112.6M | ||
| Q2 24 | — | $71.2M | ||
| Q1 24 | — | $-120.0M |
自由现金流率BLLNEXAS
| Q4 25 | — | 13.7% | ||
| Q3 25 | 7.7% | 22.3% | ||
| Q2 25 | — | 5.8% | ||
| Q1 25 | — | -0.1% | ||
| Q4 24 | — | 1.5% | ||
| Q3 24 | — | 15.9% | ||
| Q2 24 | — | 10.2% | ||
| Q1 24 | — | -18.8% |
资本支出强度BLLNEXAS
| Q4 25 | — | 3.6% | ||
| Q3 25 | 8.8% | 3.5% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 5.1% | ||
| Q1 24 | — | 5.9% |
现金转化率BLLNEXAS
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
